Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04809818 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate Safety and PK of Multiple Doses of LT3001 Drug Product and Drug-drug Interaction in Healthy Subjects
A Phase 1 study, sponsored by Lumosa Therapeutics Co..
- Completed
- Registry status
- Phase 1
- Development phase
- 65
- Enrollment target
NCT04809818 is a Phase 1 study that has completed, run by Lumosa Therapeutics Co.. The registered enrollment target is 65 participants.
The verdict
NCT04809818, a Phase 1 study, has completed, sponsored by Lumosa Therapeutics Co..
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 65 participants
- Enrollment target
Study Summary
This Phase 1 study is planned to establish the clinical safety and pharmacokinetics profile of multiple dose of LT3001 drug product and to investigate drug interactions of LT3001 with potential concomitant medications in healthy subjects.
Interventions
- DRUG Placebo
- DRUG Aspirin
- DRUG Apixaban
- DRUG Clopidogrel
- DRUG LT3001 drug product
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2021-03-21 |
| Est. Completion | 2021-08-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04809818
The ClinicalTrials.gov registry entry for NCT04809818 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 65 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Lumosa Therapeutics Co., which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT04809818 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04809818 about?
NCT04809818 is a clinical study titled "A Study to Evaluate Safety and PK of Multiple Doses of LT3001 Drug Product and Drug-drug Interaction in Healthy Subjects". This Phase 1 study is planned to establish the clinical safety and pharmacokinetics profile of multiple dose of LT3001 drug product and to investigate drug interactions of LT3001 with potential concomitant medications in healthy subjects.
What is the current status of trial NCT04809818?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 65 participants. The study started on 2021-03-21. Estimated completion is 2021-08-05.
What interventions are being tested in trial NCT04809818?
The interventions under investigation include: Placebo (DRUG), Aspirin (DRUG), Apixaban (DRUG), Clopidogrel (DRUG), LT3001 drug product (DRUG).
Who is sponsoring clinical trial NCT04809818?
This trial is sponsored by Lumosa Therapeutics Co., which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.